You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 803 Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials in-progress
803 Phase 1/2 study using ENB-003, a first-in-class selective ETBRi, in combination with pembrolizumab in subjects with advanced refractory solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020137011
Dec 20202604
Jan 20214602
Feb 20216204
Mar 20218606
Apr 20215009
May 2021606
Jun 2021007
Jul 2021208
Aug 2021108
Sep 20210015
Oct 202148027
Nov 202150028
Dec 20211602
Jan 20225809
Feb 20225208
Mar 20222202
Apr 20226403
May 20223604
Jun 202290010
Jul 20225603
Aug 20226607
Sep 20224606
Oct 20223006
Nov 20223603
Dec 20225001
Jan 20236805
Feb 20237802
Mar 20234601
Apr 202358011
May 20233604
Jun 20233605
Jul 202366011
Aug 20235406
Sep 20233204
Oct 202352010
Nov 20238605
Dec 20234004
Jan 20241202
Feb 20245603
Mar 202450027
Apr 202444013
May 20246906
Jun 20246303
Jul 202418606
Aug 20246408
Sep 20245806
Oct 20247808
Nov 2024114016
Dec 20245605
Jan 20256608
Feb 20252409
Mar 20250010
Apr 2025006
May 20250011
Jun 2025008
Total27280422